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The structural biogenesis and functional proficiency of the multiheteromeric complexes
forming the mitochondrial oxidative phosphorylation system (OXPHOS) require the con-
certed action of a number of chaperones and other assembly factors, most of which are
specific for each complex. Mutations in a large number of these assembly factors are re-
sponsible for mitochondrial disorders, in most cases of infantile onset, typically character-
ized by biochemical defects of single specific complexes. In fact, pathogenic mutations in
complex-specific assembly factors outnumber, in many cases, the repertoire of mutations
found in structural subunits of specific complexes. The identification of patients with spe-
cific defects in assembly factors has provided an important contribution to the nosological
characterization of mitochondrial disorders, and has also been a crucial means to identify
a huge number of these proteins in humans, which play an essential role in mitochondrial
bioenergetics. The wide use of next generation sequencing (NGS) has led to and will allow
the identifcation of additional components of the assembly machinery of individual com-
plexes, mutations of which are responsible for human disorders. The functional studies on
patients’ specimens, together with the creation and characterization of in vivo models, are
fundamental to better understand the mechanisms of each of them. A new chapter in this
field will be, in the near future, the discovery of mechanisms and actions underlying the
formation of supercomplexes, molecular structures formed by the physical, and possibly
functional, interaction of some of the individual respiratory complexes, particularly complex
I (CI), III (CIII), and IV (CIV).
Introduction
The oxidative phosphorylation system (OXPHOS) consists of five multiheteromeric complexes embed-
ded in the inner mitochondrial membrane. The first four complexes (complex I, CI; complex II, CII;
complex III, CIII; complex IV, CIV or cytochrome c (cyt c) oxidase, COX), together with two mobile
electron shuttles, ubiquinone (coenzyme Q, CoQ) and cyt c, form the respiratory chain (RC). Electron
transport through RC generates energy, which is partly used by CI, CIII, and CIV to pump protons across
the inner mitochondrial membrane thus creating an electrochemical potential (P). P constitutes the
driving protonmotive force for the production of ATP, operated by complex V (CV or ATP synthase), but
also for heat production, Ca++ import inside mitochondria and homeostasis, protein translocation across
mitochondrial membranes etc.
The genetic basis of the OXPHOS is unique, with the involvement of both nuclear and mtDNA. With
the exception of CII, all the OXPHOS complexes contain subunits encoded by mtDNA: seven (MTND1,
2, 3, 4, 4L, 5, 6) are components of CI, one (cytochrome b) of CIII, three (MTCOI, II, III) of CIV, two
(ATPase 6 and 8) of CV.
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As a consequence, the assembly of eachOXPHOS complex requires the insertion ofmtDNA-encoded subunits into
the inner membrane of mitochondria, in concert with tens of subunits encoded by nuclear genes; the synthesis and
incorporation of several prosthetic groups that form the catalytic cores for redox reactions and the final formation of
functionally active holocomplexes. Individual holocomplexes can also interact with each other forming mammoth
structures called respiratory supercomplexes. A more detailed description of the role of these genes and the basic
mechanisms of CI–V assembly is reported in a dedicated paper by Signes and Fernandez-Vizarra [1] in this issue.
Mitochondrial disorders are genetic defects affectingOXPHOS either ‘directly’ (e.g.OXPHOS subunits or assembly
factors) or by impairing processes related to the proper formation ofOXPHOS (e.g. mtDNA replication, transcription
and translation, biosynthesis of RC cofactors, mitochondrial biogenesis, . . . ). The former group is usually character-
ized by isolated biochemical defects, affecting a single complex, whereas the latter is typically associated withmultiple
OXPHOS deficiency. The structural and functional complexity of the biochemical pathways underpinningOXPHOS,
explain the extreme heterogeneity of inherited mitochondrial disorders, which include a vast range of symptoms,
severity, age of onset, progression, and outcome [2,3]. The prevalence of genetic OXPHOS defects is approximately
1:5000 live births, just considering mtDNAmutations [4], and even higher by including some frequent nuclear gene
mutations [5,6]. Because OXPHOS is necessary for energy supply to virtually any cell, any organ can be affected by
mitochondrial disease. However, the most common clinical presentations include the involvement of muscle, heart
and brain, i.e. post-mitotic, specialized tissues, with high metabolic requests [7].
This review will be focussed on factors involved in assembly of human OXPHOS complexes, and associated with
human diseases (Table 1). Any protein that plays a role in formation or stability of an OXPHOS complex, not being
stable part of it, can be considered an ‘assembly factor’. However, in only a few cases the detailed mechanism of action
of these factors has been elucidated, so that the definition of ‘assembly factor’ remains largely observational, based on
the association between an assembly defect of a given complex with mutations in a particular gene product.
Several genes encoding enzymes or proteins with a role in synthesis of prosthetic groups and cofactors have been
classified as ‘assembly factors’ in the past: e.g. COX10 and COX15, encoding enzymes involved in the terminal steps
of the biosynthesis of hemes a and a3; synthesis of cytochrome oxidase 1 and 2 (SCO1 and SCO2), involved in cel-
lular copper homeostasis. Clinical presentations associated with mutations in these genes are briefly described in
this manuscript. Several enzymes, chaperones and transporters are necessary for the biosynthesis of the iron–sulphur
(Fe–S) clusters and the corresponding genetic defects are usually associated with multiple biochemical defects in-
volving RC complexes containing Fe–S centers, namely cI, cII and cIII. Recent reviews describe in detail this group
of diseases [8,9]. Moreover, proteins/enzymes related to the synthesis of the RC electron shuttles, CoQ and cyt c,
have been sometimes considered as ancillary factors for the OXPHOS system; the human diseases associated with
CoQ deficiency have been reviewed elsewhere [10]. Examples of these genes are reported in Table 1 but will not be
described in detail in this review.
Human diseases associated with CI deﬁciency (MIM 252010)
Approximately one-third of all cases with mitochondrial disorders are biochemically characterized by an isolated CI
deficiency [11,12]. A large percentage still lacks amolecular diagnosis, because of the complexity of this huge enzyme,
its dual genetic origin, and the incomplete information about its assembly, turnover, and regulation. The clinical
presentations are highly heterogeneous, including, for children, Leigh syndrome (LS), neonatal cardiomyopathy with
lactic acidosis, fatal infantile lactic acidosis (FILA), macrocystic leukoencephalopathy, or isolated myopathy [13,14].
Similar to other CI defective conditions, mutations in CI assembly factors cause a wide range of clinical disorders.
NDUFAF1 (MIM 606934)
NDUFAF1 (previously known as CIA30) has been shown to interact with mitochondrial and nuclear CI subunits
[15] and is physically associated with two assembly intermediates [16]. Mutations in NDUFAF1 were reported in
two unrelated patients with cardiomyoencephalopathy, lactic acidosis, and reduced levels of CI [15,17]. Both patients
developed hypertrophic cardiomyopathy in infancy after a viral illness. More recently, NDUFAF1 mutations were
found in a child with leukodystrophy, peripheral neuropathy, and CI deficiency [18].
NDUFAF2 (MIM 609653)
A stopmutation of NDUFAF2 (B17.2L orNDUFA12L) was detected in a patient with progressive leukoencephalopa-
thy with vanishing white matter, and impaired CI assembly [19]. A different mutation, which affects the first methio-
nine, was found in two infants with hypotonia, nystagmus, and ataxia [20] associated with reduced CI activity in
muscle. Additional homozygous NDUFAF2 mutations were identified in LS patients [21,22].
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Table 1 Assembly factors of the OXPHOS with their (predicted) functions and related mitochondrial disease
Gene/protein OMIM (Predicted) function(s)* Associated phenotypes
CI assembly factors
NDUFAF1 606934 CI chaperone; transient interaction with early arm membrane
intermediates (ND2 module)
Cardiomyoencephalopathy, lactic acidosis; leukodystrophy,
neuropathy
NDUFAF2 609653 Stabilizer of late intermediate (N module) Leukoencephalopathy with vanishing white matter, Leigh
syndrome
NDUFAF3 612911 Interacts with some CI subunits and with NDUFAF4 (Q module) Variable phenotypes: macrocephaly, severe muscle
weakness, myoclonic seizures, brain leukomalacia; Leigh
syndrome
NDUFAF4 611776 Interacts with some CI subunits and with NDUFAF3 (Q module) Encephalopathy, antenatal cardiomyopathy, Leigh syndrome
NDUFAF5 612360 Probable methyltransferase of NDUFS7; early arm membrane
assembly
Leigh syndrome, progressive spasticity
NDUFAF6 612392 Probable role in the assembly/stability of the Q module Leigh syndrome; Acadian variant of Fanconi syndrome
NDUFAF7 615898 Methyltransferase of NDUFS2; stabilizer of early intermediate(s) Pathologic myopia
ACAD9 611103 CI ND2 module assembler by the interaction with NDUFAF1,
ECSIT and TMEM126B (MCIA)
Cardiomyopathy, encephalopathy, lactic acidosis, exercise
intolerance
FOXRED1 613622 Mid-late stages of CI assembly (ND4 module) Leigh syndrome; microcephaly and cardiomyopathy
TIMMDC1 615534 Assembly of membrane-embedded (ND1 module) and soluble
arms of CI
Variable neurological phenotypes: Leigh syndrome; seizures,
hypotonia, deafness, peripheral neuropathy, nystagmus
TMEM126B 615533 Assembly of the mature CI from the ND2 module 315- and
370-kDa subcomplexes
Exercise intolerance; cardiomyopathy and renal tubular
acidosis
CII assembly factors
SDHAF1 612848 Fe/S clusters insertion into SDHB Leukoencephalopathy
SDHAF2 613019 Flavination of SDHA Hereditary paraganglioma
CIII assembly factors
BCS1L 603647 Incorporation of UQCRFS1 GRACILE syndrome, Bjornstad syndrome, encephalopathy,
proximal tubulopathy and liver failure
TTC19 613814 Binding to fully assembled CIII dimer, role on UQCRFS1
turnover
Progressive encephalopathy, ataxia, psychiatric symptoms
LYRM7 615831 Binding and stabilization of UQCRFS1 and interaction with
components of an Fe–S transfer complex for CIII
Leukcoencephalopathy, liver failure
UQCC2 614461 Interacts with UQCC1; synthesis of cyt b and the ﬁrst steps of
CIII assembly
Lactic acidosis, dysmorphic features; respiratory distress and
seizures
UQCC3 616097 Cardiolipin-binding protein; stabilizer of CIII and CIII
supercomplexes
Lactic acidosis, hypoglycemia, hypotonia, and delayed
development
CIV assembly factors
SURF1 185620 Formation of the early MTCO1 subcomplexes Leigh syndrome
COA3/MITRAC12 614775 Interaction with early COX intermediates and assembly factors Exercise intolerance and neuropathy
COA5/C2ORF64 613920 Involved in a very early step of the COX assembly Fatal neonatal cardiomyopathy
COA7 615623 Unknown Ataxia and neuropathy
COX14/c12orf62 614478 Coupling synthesis of MTCO1 with assembly into COX
holoenzyme
Respiratory and neurologic distress, metabolic acidosis and
neonatal death
COX20/FAM36A 614698 Involved in early steps of the COX assembly; interaction with
MTCO2
Ataxia and muscle hypotonia, dystonia-ataxia
PET100 614770 Involved in intermediate stage of COX assembly Psychomotor delay, seizures, hypotonia, and Leigh syndrome
PET117 614771 Coupling Heme a synthase activity to COX assembly.
Interaction with PET100
Neurodevelopmental regression
APOPT1 616003 Unknown Leukoencephalopathy
Copper incorporation
COA6 614772 Copper homeostasis and transport to CIV Fatal infantile cardioencephalomyopathy
SCO1 603644 Incorporation of copper atoms in the catalytic sites of the
nascent CIV
Infantile encephalopathy, neonatal hepatopathy, ketoacidotic
comas
SCO2 604272 Incorporation of copper atoms in the catalytic sites of the
nascent CIV
Infantile cardioencephalomyopathy, myopia, CMT
Heme biosynthesis
COX10 602125 Heme A synthesis (conversion of heme b into heme o) Leigh syndrome, proximal renal tubulopathy, hypertrophic
cardiomyopathy, sensorineural deafness, metabolic acidosis
COX15 603646 Heme A synthesis (conversion of heme o into heme a) Infantile cardiomyopathy, Leigh syndrome
CV assembly factors
ATPAF2 608918 F1 chaperone; essential for assembly of α + β heterooligomer Degenerative encephalopathy, connatal lactic acidosis,
methyl glutaconic aciduria
TMEM70 612418 Assembly of F1; structure of cristae Neonatal encephalocardiomyopathy
Continued over
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Table 1 Assembly factors of the OXPHOS with their (predicted) functions and related mitochondrial disease (Continued)
Gene/protein OMIM (Predicted) function(s)* Associated phenotypes
Fe–S biosynthesis
BOLA3 613183 Speciﬁc Fe–S cluster targetting factor Epileptic encephalopathy, cardiomyopathy, spasticity
(MMDS2)
FDXR 103270 Ferredoxin reductase Auditory neuropathy, optic atrophy
FXN 606829 Iron chaperone Friedreich’s ataxia
GLRX5 609588 Fe–S cluster transfer to apoproteins Sideroblastic anemia, spasticity
IBA57 615316 Required for [4Fe–4S] cluster assembly Leukodystrophy, hypotonia, dysmorphism, SPOAN (MMDS3)
ISCA1 611006 Required for [4Fe–4S] cluster assembly Leukodystrophy, epilepsy (MMDS5)
ISCA2 615317 Required for [4Fe–4S] cluster assembly Leukodystrophy (MMDS4)
ISCU 611911 Scaffold protein for Fe-S cluster synthesis Myopathy, hypertrophic cardiomyopathy
LYRM4/ISD11 613311 Fe-S protein biogenesis desulphurase interacting protein Respiratory distress, hypotonia, hepatopathy
NFS1 603485 Cysteine desulphurase Lactic acidosis, hypotonia, multisystem organ failure
NFU1 608100 Scaffold protein for [4Fe–4S] cluster synthesis Hypotonia, leukodystrophy, epilepsy (MMDS1)
NUBPL 613621 Facilitates the assembly of Fe–S cofactors and subunits in CI Leukodystrophy, myopathy, ataxia (CI deﬁciency)
Cofactor and cytochrome biosynthesis
HCCS 300056 Synthesis of cyt c1 and cyt c MIDAS
CYCS 123970 cyt c Thrombocytopenia
FLAD1 610595 Synthesis of FAD Lipid storage myopathy
CoQ10
ADCK3/COQ8A 606980 CoQ10 biosynthesis Cerebellar ataxia
ADCK4/COQ8B 615567 CoQ10 biosynthesis Nephrotic syndrome, proteinuria
COQ2 609825 Parahydroxybenzoate-polyprenyltransferase Encephalomyopathy; cardiomyopathy and renal failure;
ataxia; Leigh syndrome; isolated myopathy
COQ4 612898 CoQ10 biosynthesis Cardiac or neurologic involvement
COQ6 614647 Flavin-dependent monooxygenase Nephrotic syndrome, seizures
COQ7 601683 Di-iron oxidase Neonatal complex multisystem disorder
COQ9 612837 CoQ10 biosynthesis Encephalopathy, microcephaly
PDSS1 607429 Trans-prenyltransferase (subunit 1) Early-onset multisystem disorder
PDSS2 610564 Trans-prenyltransferase (subunit 2) Fatal encephalomyopathy and nephrotic syndrome
Abbreviations: CMT, Charcot–Marie–Tooth; Fe–S, iron–sulphur; FOXRED, FAD-dependent oxidoreductase-containing domain 1; GRACILE, growth re-
tardation, aminoaciduria, cholestasis, iron overload, lactic acidosis, early death; MIDAS, microphthalmia, dermal aplasia and sclerocornea; MMDS,
multiple mitochondrial dysfunctions syndrome; NUBPL, nucleotide-binding protein like; SCO, synthesis of cytochrome oxidase 1; SCO2, synthesis of
cytochrome oxidase 2; SDHAF, SDH assembly factor 1; SPOAN, spastic paraparesis, peripheral neuropathy +− optic nerve atrophy; UQCRFS1, Rieske
Fe–S protein.
*A detailed description of the functions of the assembly factors is reported in a dedicated paper by Signes and Fernandez-Vizarra [1] in this issue.
NDUFAF3 (MIM 612911)
Mutations in NDUFAF3/C3ORF60 were found in three families with CI deficiency associated with a spectrum of
severe phenotypes: a fulminant syndrome dominated by muscle hypertonia in the first, macrocephaly and severe
muscle weakness in the second, myoclonic epilepsy and leukomalacia in the third. All patients died before 6 months
of age [23]. LS has been recently described as a clinical feature of NDUFAF3 deficiency [24].
NDUFAF4 (MIM 611776)
A homozygous mutation in NDUFAF4/C6ORF66 was associated with severe CI deficiency in five consanguineous
patients presenting with infantile encephalopathy and in one unrelated case of antenatal cardiomyopathy. Reduction
in fully assembled CI and accumulation of assembly intermediates was observed in patients’ mitochondria [25].
NDUFAF5/C20ORF7 (MIM 612360)
Ahomozygousmutation in an anonymous gene,C20ORF7 (nowNDUFAF5), was identified in a lethalneonatal form
ofCI deficiency by homozygositymapping followed by candidate gene analysis [26]. AdditionalNDUFAF5mutations
were later found in subjects with LS [27,28]. Interestingly, some patients show combined deficiency of CI and CIV,
suggesting for NDUFAF5 an additional role in CIV assembly or in the formation of CI–CIV supercomplexes.
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NDUFAF6 (MIM 612392)
A homozygous missense mutation in a conserved residue of NDUFAF6 was associated with LS with isolated CI defi-
ciency [29]. Later, biallelicmissensemutations inNDUFAF6were identified in childrenwith LS due tomitochondrial
complex I deficiency [30-32]. Notably, a homozygous ultra-rare non-coding variant (rs575462405) located in intron
2 of NDUFAF6 was found in nine patients with the Acadian variant of Fanconi syndrome. This variant impairsND-
UFAF6 splicing and affected kidney and lung showed specific loss of the mitochondria-located NDUFAF6 isoforms
[33].
NDUFAF7 (MIM 615898)
A heterozygous mutation in NDUFAF7 was recently proposed as causative in a Chinese family with pathologic my-
opia. This variant segregated within the family; impaired complex I activity and decreased ATP levels were found in
cultured patient’s cells [34].
ACAD9 (MIM 611103)
Mutations inACAD9 are quite frequent and associated with infantile hypertrophic cardiomyopathy, encephalopathy,
and lactic acidosis [35-37]. All patients had a reduction in CI enzymatic activity and assembly. Severe neonatal pre-
sentations [38] and multiorgan involvement, with liver and kidney damage [39], broaden the phenotypic spectrum of
ACAD9 disease. Most of the ACAD9 mutant cells and patients respond to riboflavin treatment, with partial correc-
tion of CI deficiency and clinical improvement [35,40], possibly because ACAD9 is an FADH2-dependent acyl-CoA
dehydrogenase. Nevertheless, non-responsive patients have been reported [41]. The surviving patients often develop
delayed-onset neurologic or muscular symptoms [37]. Patients with missense mutations are usually mildly affected,
with childhood onset cardiomyopathy [42] or lifetime exercise intolerance and lactic acidosis [40,43].
ACAD9 displays a β-oxidative activity in vitro but fatty acid β-oxidation has been reported as normal in most
patients with ACAD9 mutations. However, the enzymatic activity of ACAD9, required for full fatty acid oxidation
capacity, was suggested to be important in cells expressing high levels of ACAD9 (neurones and liver), thus impair-
ment of this function may contribute to the phenotype [44].
FOXRED1 (MIM 613622)
FAD-dependent oxidoreductase-containing domain 1 (FOXRED1) was identified by gene screening of CI-defective
patients with LS [21] or encephalocardiomyopathy [45]. A homozygousmissensemutation was identified in a subject
with epilepsy and severe psychomotor retardation, associated with severe reduction in CI and a mild decrease in CII.
The authors suggested that FOXRED1 may play a role in the assembly of two flavoprotein-containing OXPHOS
complexes [46].
TIMMDC1 (MIM 615534)
A homozygous intronic TIMMDC1 mutation was identified in three unrelated patients with mitochondrial CI de-
ficiency [47]; the nucleotide change results in aberrant splicing and premature termination. Both TIMMDC1 RNA
and protein showed severely decreased expression. All patients had severe early-onset neurologic dysfunctions (e.g.
hypotonia, failure to thrive, sensorineural deafness, peripheral neuropathy, nystagmus, seizures).
TMEM126B (MIM615533)
Biallelic mutations in TMEM126B were reported in patients with CI deficiency and exercise intolerance affecting
only skeletal muscle [48] and in one subject presenting a more severe phenotype with hypertrophic cardiomyopathy
and renal tubular acidosis [49].
NUBPL/Ind1 (MIM 613621)
Fe–S clusters are present in CI, CII and CIII, and several enzymes are required for their biosynthesis (Table 1). How-
ever NUBPL (nucleotide-binding protein like) has a specific role in the incorporation of Fe–S centers into CI [50].
Compound heterozygous NUBPLmutations were first identified in a single case, presenting with mitochondrial en-
cephalopathy and CI deficiency [21] and then in six subjects with the same biochemical defect and a characteristic
leukoencephalopathic pattern on brain MRI [51].
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Human diseases associated with CII deﬁciency (MIM 252011)
Isolated defect of CII is a rare biochemical finding, observed in<10% of OXPHOS defective cases [52,53]. Two main
clinical presentations have been reported: mitochondrial encephalomyopathy and familial paragangliomas.
In the first group, LS is the most common clinical and neuropathological presentation; additional phenotypes
includemyopathy, encephalopathy, leukodystrophy, and isolated cardiomyopathy. The pathogenesis ofCII-associated
paragangliomas/pheochromocytomas remains to be explained. The most widely accepted hypothesis is based on
induction of the hypoxia program that switches energymetabolism frommitochondrial respiration to glycolysis [54].
Mutations in genes encoding for either structural subunits or assembly factors have been described (SDHA, SDHB,
SDHD, and SDH assembly factor 1 (SDHAF1) for mitochondrial diseases; SDHD, SDHC, SDHB, SDHA, and
SDHAF2 for hereditary paragangliomas). Defects in several factors involved in FAD (e.g. FLAD1) [55] or Fe–S
cluster synthesis (e.g. IBA57, ISCU) [56,57] can impair assembly and activity of CII, as well as of other Fe–S or
FAD-dependent enzymes; however, only four are presently known as specific CII assembly factors (SDHAF1–4).
Mutations in two of them, namely SDHAF1 [53] and SDHAF2 [58], have been associated with human pathologies.
SDHAF1 (MIM612848)
SDHAF1, standing for SDH Assembly Factor 1, is a small protein containing an LYR motif characteristic of pro-
teins involved in Fe–S metabolism [53]. SDHAF1 was shown to contribute to Fe–S cluster incorporation into the
CII subunit SDHB [59]. Mutations in this protein are associated with drastic decrease in CII activity and content in
both humans and yeast. Homozygous missense (and one nonsense) mutations in SDHAF1 have been identified in
affected subjects from six families, presenting with leukoencephalopathy; a peculiar hallmark was accumulation of
lactate and succinate in the white matter [53,59,60]. To date, no mutation in SDHAF1 has been reported in patients
with paraganglioma [61].
SDHAF2 (MIM 613019)
The function of SDHAF2 is likely related to the flavination of the subunit SDHA [58]. The binding of FAD to SDHA
is probably a self-catalytic process, but requires that the imported SDHA subunit is properly refolded, forming the
FAD-binding pouch. Sdhaf2/SDHAF2 could be a chaperone responsible for this step [62].
A germlinemissensemutation in SDHAF2,G78R, has been reported in two large families with hereditary,multiple
head and neck paragangliomas (PGL2). Haplotype analysis indicated that the G78R occurred independently in the
two families [63]. The G78 residue is highly conserved and the mutant R78 was demonstrated to alter its interaction
with the SDHA subunit [58]. Additional patients harboring nonsense or heterozygous SDHAF2mutations, presented
with benign head and neck PGLs [61,64]. A variant in 3′-UTR was reported in two unrelated subjects with adrenal
pheochromocytoma [65].
Human diseases associated with CIII deﬁciency (MIM
124000)
CIII defects are rare, compared with those of CI or CIV. CIII deficiency is caused by recessively inherited mutations
affecting nuclear encoded structural subunits or assembly factors, and is associated with a wide range of clinical
presentations and reduced CIII activity/amount [66]. CIII deficiency may also, and relatively frequently, be due to
mutations in the mtDNA geneMTCYB, typically associated with myopathy and exercise intolerance.
In the recent years, the introduction of next generation sequencing (NGS) techniques, together with the discovery
of additional assembly factors in yeast, has led to the identification of more disease genes encoding CIII-assembly
factors, in addition to mutations of BCS1L, which were discovered in 2001 [67].
BCS1L (MIM 603647)
Several BCS1L gene mutations have been reported in CIII deficiency, associated with different clinical presentations
ranging from multisystem involvement including neonatal proximal tubulopathy, hepatopathy, and encephalopathy,
to isolated neurological syndrome with long-term survival [67-69]. Specific syndromes can be caused by BCS1L
mutations. The acronym GRACILE stands for growth retardation, aminoaciduria, cholestasis, iron overload, lactic
acidosis and early death, and designates an infantile condition caused by a specific BCS1L mutation, S78G, which
is part of the Finnish disease heritage [70]. A less-severe phenotype associated with BCS1L missense mutations is
Bjo¨rnstad syndrome, characterized by neurosensory hearing loss and abnormally curly and brittle hair (pili torti).
The clinical heterogeneity could be linked to the functional domain affected by the different missensemutations [71].
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Fewnonsensemutations as well as variants in splice sites and in the 5’-UTRof theBCS1LmRNAhave also been found
[72,73]. All BCS1L mutations are associated with isolated CIII deficiency (rarely in combination with reduced CIV
and CI activities) and reduced amount of Rieske Fe–S protein (UQCRFS1) incorporated into CIII.
TTC19 (MIM 613814)
TTC19 mutations have been reported in a few patients with heterogeneous phenotypes ranging from early onset
neurodegenerative disorders [74,75] to adult forms with psychiatric manifestations and cerebellar ataxia [76,77]. In
TTC19-mutant cases, ataxia and impairment of cortical functions leading to language or cognitive regression are the
clinical hallmarks of infantile-onset forms, whereas psychiatric symptoms are typical of juvenile-adult forms. MRI
patterns are consistent with Leigh or Leigh-like syndrome. Decreased cIII activity was present in almost all patients
reported to date, while lactic acidosis seems not to be a reliable biomarker [78]. Notably,most of theTTC19mutations
are nonsense or frameshift changes; a few missense mutations have been described, associated with the absence or
strong reduction in the protein [79].
LYRM7 (MIM 615831)
As SDHAF1, LYRM7 contains an LYR motif, the molecular signature of proteins involved in the delivery of Fe–S
clusters [80]. A homozygous missense mutation was found in a CIII-deficient patient who showed severe, acute, and
ultimately fatal neurologic decompensation and regression after having had 20-month long normal development [81].
Six different homozygous mutations were later reported in patients with defects of mitochondrial complex III and a
similar and distinct pattern of leukoencephalopathy on brain imaging [82]. A homozygous, truncating, mutation in
LYRM7was found in a childwith complex III defect and acute liver dysfunction with lactic acidosis [83], a phenotype
resembling BCS1L patients.
QCC2 (MIM 614461)
A homozygous splice site mutation in UQCC2 was first described in a boy with lactic acidosis, mild dysmorphic
features, delayed neurological development and sensorineural hearing impairment. This subject had CIII deficiency
but also presented secondary reduction in CI and CIV activities [84]. Recently, a second case was published: a girl
with respiratory distress and severe epileptic seizures, born after a pregnancy complicated by intrauterine growth
retardation and oligohydramnios, who died at 1 month of age. Two homozygous missense variants in UQCC2 were
identified, and a severe reduction in UQCC2 protein was demonstrated [85].
UQCC3 (MIM 616097)
A homozygous missense mutation in UQCC3 was identified in a patient diagnosed with isolated CIII deficiency,
displaying lactic acidosis, hypoglycemia, hypotonia, and delayed development without dysmorphic features [86].
UQCC3 was shown to be a cardiolipin-binding protein involved in the stabilization of CIII-containing supercom-
plexes [87].
CIII defects with different genetic bases, with the exception of TTC19 deficiency, often present a combined RC de-
ficiency. BesidesCIII,CI and, in some cases,CIV activities are decreased [84,88]. The presence of fully assembled CIII
is probably necessary for the stability or assembly ofCI and CIV, whichmight be related to respirasome/supercomplex
formation.
Human diseases associated with CIV deﬁciency (MIM
220110)
Together with defects of CI, CIV (or COX) deficiencies are quite common biochemical hallmarks of mitochondrial
disease. In infancy, themost frequent manifestation of isolated and severe COX deficiency is LS, but other encephalo-
cardiomyopathy phenotypes are known. Several mutations of mtDNA tRNA genes are associated with maternally
inherited COX defects. Conversely, only a few mutations in the genes encoding structural COX subunits (either
mtDNA- or nuclear-encoded, e.g. MTCO1, MTCO2, MTCO3, COX6B, COX7B, COX8A) have been reported to
date, suggesting that most of the mutations in structural components of CIV are incompatible with extrauterine life.
Accordingly, the most common defects of COX are due to mutations in nuclear DNA genes coding for assembly
factors or for enzymes/proteins with a role in biosynthesis/incorporation of CIV prostetic groups.
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SURF1 (MIM 185620)
Mitochondrial protein SURF1 is a specific assembly factor of COX, but its function is poorly understood. Mutations
in SURF1 are the most common cause of LS associated with COX deficiency [89]. This association is specific, and is
partly explained by the observation that almost all the SURF1 mutations reported to date cause the complete absence
of the protein.Very fewmissensemutations have been detected [90], sometimes in associationwith less severe pheno-
types [91]. Nevertheless, no clear genotype–phenotype correlations are detectable amongst these patients [92]. Even
amongst subjects who showed an unusual long survival, COX activity was not detectable or strongly reduced, includ-
ing cases harboring a SURF1 variant that abolish the initiation codon [93]. In addition to LS, a peculiar phenotype
that has been associated with SURF1mutations is Charcot–Marie–Tooth disease type 4K, an autosomal recessive de-
myelinating peripheral neuropathy characterized by onset in the first decade of distal muscle weakness and atrophy,
with muscle CIV deficiency [94].
In SURF1 null human samples [89], fully assembled, functionally active CIV is found in residual amounts, sug-
gesting partial functional redundancy. Studies based on mouse models revealed tissue-specific and species-specific
differences in COX biogenesis and COX ability to incorporate into respiratory supercomplexes, supporting the view
that COX assembly is much more dependent on SURF1 in humans than in mice [95].
COA3/MITRAC12 (MIM 614775)
COA3was identified in immunoprecipitation studies as a protein interacting with central CIV subunits, e.g.MTCO1,
and assembly factors, e.g. SURF1 and COX14 [96]. Compound heterozygous mutations in COA3 were identified in
a woman with severe cIV deficiency in muscle but a relatively mild phenotype characterized by exercise intolerance,
peripheral neuropathy, obesity, and short stature [97]. The authors suggested a tissue-specific defect mainly affecting
muscle.
COA5/C2ORF64 (MIM 613920)
COA5 or C2ORF64, is the ortholog of PET191, a yeast COX assembly factor. A homozygous mutation in C2ORF64
was described in two siblings affected by fatal neonatal cardiomyopathy. The activity and amount of CIV was severely
reduced in patient fibroblasts and heart muscle, with accumulation of a small assembly intermediate containing sub-
unit MTCO1 but not MTCO2, COX4, or COX5a, indicating that C2ORF64 is involved in a very early step of COX
assembly [98].
COA7 (MIM 615623)
COA7 is a mitochondrial protein, putative COX assembly factor, without a yeast ortholog.
Biallelic pathogenicCOA7mutations were identified in a young woman, affected by early onset, progressive severe
ataxia and peripheral neuropathy, mild cognitive impairment and a cavitating leukodystrophy of the brain. Biochem-
ical analysis revealed the presence of isolated CIV deficiency in skin fibroblasts and skeletal muscle [99].
COX14/c12orf62 (MIM 614478)
By investigating three siblings with severe congenital lactic acidosis and dysmorphic features associated with a
COX-assembly defect, a homozygous mutation in C12ORF62 (now COX14) was found as the cause of the disease
[100]. Further studies suggested that COX14 is required for co-ordination of the early steps of COX assembly with
the synthesis of MTCO1 [100] and demonstrated an interaction between COX14 and MTCO1 [101].
COX20/FAM36A (MIM 614698)
COX20 associates with MTCO2 and is required for its stability; moreover, it appears to act in the early steps of CIV
assembly. A homozygous mutation in COX20 was found by analyzing candidate genes in the mutational screening
of a patient with growth retardation, hypotonia, and cerebellar ataxia [102]. The samemutation was identified in two
siblings with dystonia-ataxia syndrome. They presented with a combination of childhood-onset cerebellar ataxia,
dystonia, and sensory axonal neuropathy; biochemical analyses revealed CIV and CoQ10 deficiency in a muscle
biopsy [103]. All these patients were of Turkish origin.
PET100 (MIM 614770)
PET100 is a mitochondrial inner protein, initially described in yeast as required for the assembly of CIV [104]. A
homozygous mutation affecting the initiation codon was identified in ten affected subjects of Lebanese descent, due
to a founder effect. The patients presented with profound psychomotor delay since early infancy, seizures, hypotonia,
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and LS, associatedwith reduction inCIV activity and amount of the holoenzyme [105]. A nonsensePET100mutation
caused fatal infantile lactic acidosis, again associated with isolated CIV deficiency [106].
PET117 (MIM 614771)
PET117 is a small protein that has previously been predicted as a CIV assembly factor [101]. A homozygous nonsense
mutation was detected in two sisters with a mitochondrial disease characterized by lesions in the medulla oblongata,
and an isolated CIV deficiency with reduced levels of CIV subunits [107].
APOPT1 (MIM 616003)
APOPT1 is a mitochondrial protein deemed to initiate apoptosis by triggering release of cyt c [108]; since its levels in-
crease after oxidative challenge, a role in detoxification of reactive oxygen species has been proposed [109].APOPT1
mutations were identified in patients with brain MRI pattern characterized by cavitating leukodystrophy. The clini-
cal features of the mutant subjects varied widely from acute neurometabolic decompensation to subtle neurological
signs; all presented a chronic, long-surviving clinical course [109].
In addition to specific assembly factors, ancillary proteins are necessary for incorporation of hemes (a, a3) and
copper atoms (CuA, CuB) into catalytic subunits of CIV. Mutations in the corresponding genes are associated with
human diseases characterized by CIV deficiency.
SCO1 (MIM603644) and SCO2 (MIM 604272)
SCO1 and SCO2 promote the insertion of Cu++ atoms in the catalytic sites CuB and CuA of MTCO1 and MTCO2
subunits.Mutations in SCO2were initially found in infants with fatal cardioencephalomyopathy and COX deficiency
[110]. Heart hypertrophy in patients with SCO2 mutations is usually severe, whereas brain involvement may vary,
from LS-like to spinal muscular atrophy-like presentations [111]. Very recently, recessive SCO2mutations have been
reported in subjects with axonal polyneuropathy (Charcot–Marie–Tooth disease type 4) [112]. A peculiar dominant
phenotype was associated with a heterozygous nonsense mutation segregating with disease in a large four-generation
family with high-grade myopia [113].
Mutations in SCO1 are extremely rare and have been found in a single large family with multiple cases of neonatal
hepatopathy, severe ketoacidosis, and COX deficiency [114]. Other SCO1 cases showed fatal encephalopathy, with
or without cardiomyopathy and hepatomegaly [115,116].
COX10 (MIM 602125) and COX15 (MIM 603646)
COX10 and COX15 are enzymes involved in the terminal steps of the biosynthesis of hemes a and a3. Mutations in
COX10 are associated with a spectrum of conditions including LS, encephalopathy with proximal tubulopathy, car-
diomyopathy, sensorineural deafness, andmetabolic acidosis [117,118].Mutations of COX15 can cause fatal infantile
hypertrophic cardiomyopathy [119] and rapidly progressive or protracted LS [120].
COA6/C1orf31 (MIM 614772)
COA6 binds copper, interacts with SCO1 and can associate with MTCO2 [121]. Recessive mutations of COA6 have
been associated with fatal infantile cardioencephalomyopathy [122,123]
Human diseases associated with CV deﬁciency
Mitochondrial CV or ATP synthase deficiency due to nuclear genes mutations is often characterized by
neonatal-onset hypotonia and hypertrophic cardiomyopathy; lactic acidosis and 3-methylglutaconic aciduria are typ-
ical biochemical hallmarks of these diseases. Few disease-causing nuclear genes have been identified so far, encod-
ing assembly factors (ATPAF2, TMEM70) or structural subunits (ATP5E, ATP5A1) [124]. Furthermore, maternally
transmitted CV deficiency can be caused by mutations in the two mtDNA genes MTATP6 or MTATP8. Hetero-
plasmic missense mutations in MTATP6 [125,126] are associated with adult-onset NARP (neuropathy, ataxia, and
retinitis pigmentosa) or maternally inherited LS (MILS). Additional rare phenotypes associated withMTATP6 mu-
tations have been reported, including mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA)
[127]; adult-onset spinocerebellar ataxia [128]; motor neurone syndrome [129]. A single patient with hypertrophic
cardiomyopathy carried a nonsense mutation in MTATP8 [130], whereas few patients with hypertrophic cardiomy-
opathy and heart failure [131] or ataxia and peripheral neuropathy [132] harbored a heteroplasmic mtDNA variant,
resulting in concurrent substitutions in the overlappingMTATP6 and MTATP8 genes.
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TMEM70 (MIM 612418)
Mutations in TMEM70 are the most frequent cause of CV deficiency [133,134]. Mutations in TMEM70 were origi-
nally found in patients, mostly of Roma origin, with neonatal encephalocardiomyopathy and isolated CV deficiency
[135]. The prevalent homozygousmutation, an A-to-G transition in intron 2 of TMEM70, results in aberrant splicing
and loss of themRNA transcript; this common variant is however associatedwith highly variable clinical severity, pos-
sibly due to individual variations in nonsense-mediated RNA decay systems. Several additional patients with various
ethnic backgrounds and different mutations have been reported. The most frequent symptoms at onset are respira-
tory distress, hypotonia, cardiomyopathy, poor feeding, and psychomotor delay [136,137], often associatedwith short
stature, microcephaly, and facial dysmorphism. Typical biochemical findings are lactic acidosis, 3-methylglutaconic
aciduria, and hyperammonaemia. The outcome of thismultisystem disease dependsmainly on adequatemanagement
of neonatal hyperammonemic crises.
Samples from patients with mutations in TMEM70 showed small amounts of CV holocomplex and the pres-
ence of traces of free F1 catalytic particle of the complex [138]. Ultrastructural studies in TMEM70-mutant sam-
ples showed swollen degenerated mitochondria, cristae aggregation, and formation of concentric membrane rings
[136,139].Moreover, not onlyCV deficiencies but also impairment of otherOXPHOS complexes have been described
in TMEM70-mutant subjects. These findings indicated that CV impairment could indirectly alter other RC complex
activities by disrupting the mitochondrial cristae structure, for instance affecting the integrity of mitochondrial nu-
cleoids and hence mtDNA replication and expression.
ATPAF2 (MIM 608918)
ATPAF1 and ATPAF2 are chaperones interacting with subunits β and α of the peripheral F1 catalytic particle, es-
sential for assembly of the α+β heterooligomer [140,141]. To date, only one case of CV deficiency has been referred
to a homozygous missense ATPAF2 mutation associated with degenerative encephalopathy, connatal lactic acidosis,
and methyl-glutaconic aciduria [142]. The amount of fully assembled CV was low, but no subassembly intermediates
were detected, suggesting that ATPAF2 acts very early during CV assembly [138].
Mitochondrial supercomplexes
The vision of the OXPHOS complexes as isolated enzymes in the IM has been replaced by a model in which they as-
sociate with each other to form supramolecular structures, called supercomplexes. Supercomplexes have been shown
to be functionally active in vitro, and this has led to the hypothesis that they could facilitate substrate channeling
and electron transfer, and required for forming stable OXPHOS complexes [143-145]. Proteins requested for super-
complex assembly may exclusively include assembly factors that help assemble supercomplexes after the assembly
of individual complexes has taken place or assembly factors shared between different OXPHOS complexes. Indeed,
multiple OXPHOS deficiency or impairment of supercomplexes have been already reported in some cases harboring
mutations in genes encoding known assembly factors for ‘single’ complexes: e.g. NDUFAF2 [19], NDUFAF5 [28],
UQCC2 [85], UQCC3 [87], COA7 [99].
In addition to their recognized biological role, it is expected that in the near future there will be increasing evidence
about the significance of mitochondrial supercomplexes, and their as yet unknown assembly factors, also in medical
contexts.
Final remarks
Multiheteromeric complexes like the OXPHOS complexes need to be assembled through a finely tuned process re-
quiring many dedicated chaperones or assembly factors. The fact that four out of five OXPHOS complexes contain
subunits encoded by two different genomes (the nuclear and mtDNA) further complicates the process. Thus, it is not
surprising that impairment inOXPHOS complex assembly is linked to humandiseases.Defects of genes encoding sev-
eral assembly factors for all OXPHOS complexes are responsible for a wide variety of pathological conditions, mainly
affecting tissues/organs with high energetic demand as for other mitochondrial disorders. At biochemical analysis,
these genetic diseases are typically associated with isolated deficiencies in single specific OXPHOS complexes.
Thanks to the wide use of NGS in the diagnostic workflow of patients with clinical and/or biochemical features
suggestive for a mitochondrial disorder, the list of human diseases associated with defects in assembly of OXPHOS
complexes will probably grow up with the identification of mutations in known assembly factors still without an
associated pathological phenotype or in newly discovered assembly factors.
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Summary
• Assembly factors of themitochondrial oxidative phosphorylation (OXPHOS) system that have been
reported in the literature as responsible for many mitochondrial diseases in humans.
• Importantly, the investigation of patients with these genetic defects has allowed the identifica-
tion of several new assembly factors and contributed quite substantially to the elucidation of the
molecular mechanism in some of them.
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